Lithium carbonate
- Generic Name
- Lithium carbonate
- Brand Names
- Carbolith, Lithane, Lithmax, Lithobid
- Drug Type
- Small Molecule
- Chemical Formula
- CLi2O3
- CAS Number
- 554-13-2
- Unique Ingredient Identifier
- 2BMD2GNA4V
- Background
Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects.
- Indication
Lithium carbonate is indicated as a monotherapy for the treatment of acute manic and mixed episodes associated with bipolar 1 disorder in patients ≥7 years of age. It is also indicated as a maintenance treatment for bipolar 1 disorder in patients ≥7 years of age.
- Associated Conditions
- Bipolar 1 Disorder, Mixed manic depressive episode, Acute Manic episode
- Associated Therapies
- -
Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
- Conditions
- Interventions
- First Posted Date
- 2010-04-16
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 28
- Registration Number
- NCT01105702
- Locations
- 🇺🇸
New York University Clinical Cancer Center, New York, New York, United States
🇺🇸Overlook Hospital, Summit, New Jersey, United States
Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3
- Conditions
- Interventions
- First Posted Date
- 2010-03-30
- Last Posted Date
- 2013-01-30
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 62
- Registration Number
- NCT01096082
- Locations
- 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2010-01-25
- Last Posted Date
- 2010-01-25
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 80
- Registration Number
- NCT01055392
- Locations
- 🇧🇷
Institute of Psychiatry, Faculty of Medicine - University of Sao Paulo, Sao Paulo, SP, Brazil
Safety and Tolerability of Lithium in Spinocerebellar Ataxia 2 (SCA2)
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- Federico II University
- Target Recruit Count
- 20
- Registration Number
- NCT00998634
- Locations
- 🇮🇹
Dipartimento di Scienze Neurologiche, Napoli, Italy
Lithium in Multiple System Atrophy
- First Posted Date
- 2009-10-19
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Federico II University
- Target Recruit Count
- 10
- Registration Number
- NCT00997672
- Locations
- 🇮🇹
Dipartimento di Scienze Neurologiche, Napoli, Italy
Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression
- Conditions
- Interventions
- First Posted Date
- 2009-04-17
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 421
- Registration Number
- NCT00883493
- Locations
- 🇻🇪
Research Site, Caracas, Venezuela
Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients
- First Posted Date
- 2009-03-27
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- Wayne State University
- Target Recruit Count
- 28
- Registration Number
- NCT00870311
- Locations
- 🇺🇸
Wayne State University School of Medicine, Detroit, Michigan, United States
Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Interventions
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 84
- Registration Number
- NCT00818389
- Locations
- 🇺🇸
Cedars-Sinai ALS Center, Neurology Specialty Clinic, 8730 Alden Drive, Thalians, E 245, Los Angeles, California, United States
🇺🇸Ohio State University, Neuromuscular Division, 1654 Uphan Drive, 417 Means Hall, Columbus, Ohio, United States
🇨🇦University of Saskatchewan, Saskatoon City Hospital, 701 Queen Street, Room 7717 - 7th Floor, Saskatoon, Saskatchewan, Canada
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- Forbes Norris MDA/ALS Research Center
- Target Recruit Count
- 109
- Registration Number
- NCT00790582
- Locations
- 🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇺🇸University of Utah Clinical Neurosciences Center, Salt Lake City, Utah, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients
- Conditions
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 688
- Registration Number
- NCT00789854
- Locations
- 🇬🇧
Research Site, Winsford, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.